Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
ADEPPT is an international, multicentre, single-arm phase II trial. The protocol treatment
consists of adagrasib, which is administered at a dose of 600 mg orally, twice daily until
progression or unacceptable toxicity.The primary objective of this trial is to assess the
clinical efficacy of adagrasib treatment, in terms of objective response, in patients with
KRASG12C-mutant NSCLC, including the elderly (≥70 years) or patients with poor performance
status (ECOG PS=2).